Conditions:  Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;  Anatomic Stage IV Breast Cancer AJCC v8;  Anemia;  Ann Arbor Stage III Hodgkin Lymphoma;  Ann Arbor Stage III Non-Hodgkin Lymphoma;  Ann Arbor Stage IV Hodgkin Lymphoma;  Ann Arbor Stage IV Non-Hodgkin Lymphoma;  Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;  Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;  Castration-Resistant Prostate Carcinoma;  Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;  Hematopoietic and Lymphoid System Neoplasm;  Locally Advanced Pancreatic Adenocarcinoma;  Metastatic Breast Carcinoma;  Metastatic Malignant Solid Neoplasm;  Metastatic Pancreatic Adenocarcinoma;  Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis;  Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;  Primary Myelofibrosis;  Recurrent Acute Lymphoblastic Leukemia;  Recurrent Acute Myeloid Leukemia;  Recurrent Chronic Lymphocytic Leukemia;  Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;  Recurrent Hematologic Malignancy;  Recurrent Hodgkin Lymphoma;  Recurrent Myelodysplastic Syndrome;  Recurrent Myelodysplastic/Myeloproliferative Neoplasm;  Recurrent Myeloproliferative Neoplasm;  Recurrent Non-Hodgkin Lymphoma;  Recurrent Plasma Cell Myeloma;  Recurrent Small Lymphocytic Lymphoma;  Refractory Acute Lymphoblastic Leukemia;  Refractory Acute Myeloid Leukemia;  Refractory Chronic Lymphocytic Leukemia;  Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive;  Refractory Chronic Myelomonocytic Leukemia;  Refractory Hematologic Malignancy;  Refractory Hodgkin Lymphoma;  Refractory Malignant Solid Neoplasm;  Refractory Myelodysplastic Syndrome;  Refractory Myelodysplastic/Myeloproliferative Neoplasm;  Refractory Non-Hodgkin Lymphoma;  Refractory Plasma Cell Myeloma;  Refractory Primary Myelofibrosis;  Refractory Small Lymphocytic Lymphoma;  Stage II Pancreatic Cancer AJCC v8;  Stage III Pancreatic Cancer AJCC v8;  Stage IV Pancreatic Cancer AJCC v8;  Stage IV Prostate Cancer AJCC v8;  Unresectable Pancreatic Adenocarcinoma
Interventions:  Drug: Abemaciclib;  Drug: Abiraterone;  Drug: Afatinib;  Biological: Bevacizumab;  Drug: Bicalutamide;  Procedure: Biospecimen Collection;  Drug: Bortezomib;  Drug: Cabazitaxel;  Drug: Cabozantinib;  Drug: Capecitabine;  Drug: Carboplatin;  Drug: Celecoxib;  Drug: Cobimetinib;  Drug: Copanlisib;  Drug: Dabrafenib;  Drug: Dacomitinib;  Drug: Darolutamide;  Drug: Dasatinib;  Drug: Doxorubicin;  Biological: Durvalumab;  Drug: Enasidenib;  Drug: Entrectinib;  Drug: Enzalutamide;  Drug: Erlotinib;  Drug: Everolimus;  Drug: Fluorouracil;  Drug: Idelalisib;  Drug: Imatinib;  Biological: Ipilimumab;  Drug: Lenvatinib;  Drug: Leucovorin;  Drug: Lorlatinib;  Drug: Losartan;  Drug: Nab-paclitaxel;  Drug: Neratinib;  Biological: Nivolumab;  Drug: Olaparib;  Drug: Oxaliplatin;  Drug: Palbociclib;  Drug: Panobinostat;  Biological: Pembrolizumab;  Biological: Pertuzumab;  Drug: Ponatinib;  Other: Quality-of-Life Assessment;  Drug: Regorafenib;  Drug: Ruxolitinib;  Drug: Sirolimus;  Drug: Sorafenib;  Drug: Sunitinib;  Drug: Trametinib;  Biological: Trastuzumab Emtansine;  Drug: Tretinoin;  Drug: Vemurafenib;  Drug: Venetoclax;  Drug: Vismodegib;  Drug: Vorinostat
Sponsors:  OHSU Knight Cancer Institute;  Oregon Health and Science University
**RECRUITING NOW**
Interventions:  Drug: Abemaciclib;  Drug: Abiraterone;  Drug: Afatinib;  Biological: Bevacizumab;  Drug: Bicalutamide;  Procedure: Biospecimen Collection;  Drug: Bortezomib;  Drug: Cabazitaxel;  Drug: Cabozantinib;  Drug: Capecitabine;  Drug: Carboplatin;  Drug: Celecoxib;  Drug: Cobimetinib;  Drug: Copanlisib;  Drug: Dabrafenib;  Drug: Dacomitinib;  Drug: Darolutamide;  Drug: Dasatinib;  Drug: Doxorubicin;  Biological: Durvalumab;  Drug: Enasidenib;  Drug: Entrectinib;  Drug: Enzalutamide;  Drug: Erlotinib;  Drug: Everolimus;  Drug: Fluorouracil;  Drug: Idelalisib;  Drug: Imatinib;  Biological: Ipilimumab;  Drug: Lenvatinib;  Drug: Leucovorin;  Drug: Lorlatinib;  Drug: Losartan;  Drug: Nab-paclitaxel;  Drug: Neratinib;  Biological: Nivolumab;  Drug: Olaparib;  Drug: Oxaliplatin;  Drug: Palbociclib;  Drug: Panobinostat;  Biological: Pembrolizumab;  Biological: Pertuzumab;  Drug: Ponatinib;  Other: Quality-of-Life Assessment;  Drug: Regorafenib;  Drug: Ruxolitinib;  Drug: Sirolimus;  Drug: Sorafenib;  Drug: Sunitinib;  Drug: Trametinib;  Biological: Trastuzumab Emtansine;  Drug: Tretinoin;  Drug: Vemurafenib;  Drug: Venetoclax;  Drug: Vismodegib;  Drug: Vorinostat
Sponsors:  OHSU Knight Cancer Institute;  Oregon Health and Science University
**RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
